C9orf72 repeat expansions modify risk for secondary motor and cognitive-behavioral symptoms in behavioral-variant frontotemporal degeneration and amyotrophic lateral sclerosis

Barbara E. Spencer,[1] Sharon X. Xie,[2] Lauren Elman,[1] Colin C. Quinn,[1] Defne Amado,[1] Michael Baer,[1] Edward B. Lee,[3] Vivianna M. Van Deerlin,[3] Laynie Dratch,[1] Lauren Massimo,[1] David J. Irwin,[1] and Corey T. McMillan[1]

Abstract

In behavioral-variant frontotemporal degeneration (bvFTD) and amyotrophic lateral sclerosis (ALS), secondary motor or cognitive-behavioral symptoms, respectively, are associated with shorter survival. However, factors influencing secondary symptom development remain largely unexplored.

We performed a retrospective evaluation of the entire disease course of individuals with ALS (n=172) and bvFTD (n=69). Only individuals who had neuropathological confirmation of TDP-43 proteinopathy at autopsy or a *C9orf72* hexanucleotide repeat expansion were included for analysis. We examined the odds and hazard of secondary symptom development and assessed whether each was modified by the presence of a *C9orf72* expansion or initial clinical syndrome.

Binary logistic regression and Cox proportional hazard analyses revealed increased odds (OR=4.25 [95% CI 1.97-9.14], p<0.001) and an increased hazard (HR= 4.77 [95% CI 2.33-9.79], p<0.001) for developing secondary symptoms in those with a *C9orf72* expansion compared to those without. Initial clinical syndrome (bvFTD or ALS), age at symptom onset, and sex were not associated with development of secondary symptoms.

These data highlight the need for clinician vigilance to detect the onset of secondary motor and cognitive-behavioral symptoms in patients carrying a *C9orf72* expansion, regardless of initial clinical syndrome. *C9orf72* clinical care can be enhanced through coordination between cognitive and neuromuscular clinics.

Author affiliations:

1 Department of Neurology, University of Pennsylvania; 3400 Spruce St, Philadelphia, PA 19104, USA.

2 Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania; 3400 Spruce St, Philadelphia, PA 19104, USA.

3 Department of Pathology and Laboratory Medicine, University of Pennsylvania; 3400 Spruce St, Philadelphia, PA 19104, USA.

Correspondence to: Corey T. McMillan

Richards Laboratories
3700 Hamilton Walk
Suite 601 B
Philadelphia, PA, 19104

cmcmilla@pennmedicine.upenn.edu

Running title: FTD-ALS secondary symptom development

Keywords: epidemiology, amyotrophic lateral sclerosis, frontotemporal degeneration, dementia

Introduction

Frontotemporal degeneration (FTD) and amyotrophic lateral sclerosis (ALS) are multi-system disorders that occur along a spectrum of cognitive-behavioral and neuromuscular impairments, respectively.[1] Pathologic, genetic, and clinical features support the existence of this clinicopathologic spectrum. First, TAR DNA-binding protein ~43kDa (TDP-43) inclusions are the pathological hallmark of approximately 50% of FTD and the vast majority (>98%) of ALS cases.[2] Second, hexanucleotide repeat expansions in *C9orf72*[3,4] can cause FTD, ALS, or both, and account for ~5% of simplex and one-third of familial FTD and ALS cases.[5,6] Third, clinical overlap between FTD and ALS can occur, even in the absence of a *C9orf72* expansion, though estimates of the relative frequency of secondary symptom development vary widely.

In both FTD and ALS, the presence of secondary motor or cognitive-behavioral symptoms, respectively, is associated with shorter survival.[7–10] Therefore, understanding the risk of secondary symptoms within FTD and ALS is critical, yet factors influencing the risk of secondary symptom development remain largely unexplored.

Previous studies estimate that ~9-15% of individuals with ALS eventually develop frank FTD, though 30-50% develop some level of cognitive impairment.[1,11–15] Recently, using appropriate normative data, we found that ~15% of individuals with ALS have cognitive impairment.[16] Likewise, ~4-14% of individuals with FTD develop a secondary motor impairment consistent with ALS,[17–20] a number that may underestimate the incidence since latent evidence of neuromuscular impairment is rarely assessed. Estimates of secondary motor or cognitive-behavioral symptom development specifically in those with disease due to a *C9orf72* expansion vary widely (~11-60%).[3,21–25] It is difficult to compare estimates across studies which use different criteria to determine the presence of secondary symptoms. In several studies that directly compare persons with *C9orf72* expansions to those without *C9orf72* expansions, a higher frequency of secondary symptom development has been reported in individuals with *C9orf72* expansions (23-50%) compared to those without *C9orf72* expansions (4-12%). [26–28] However, research limited to individuals with *C9orf72* expansions likely overestimate concomitant FTD and ALS.

A further major limitation of prior research evaluating secondary symptom development in FTD and ALS is the reliance on clinically- rather than neuropathologically-defined cases. Upper and/or lower motor neuron symptoms are extraordinarily rare in FTD due to

underlying tau pathology.[29,30] Tau pathology accounts for nearly half of all FTD cases and is not easily clinically differentiated from FTD due to underlying TDP-43. Thus, secondary ALS in FTD is likely underestimated when individuals without an underlying TDP-43 proteinopathy are included in risk models.

Recent evidence suggests that the risk of developing secondary ALS in individuals with an initial presentation of FTD decreases with time from FTD symptom onset.[27] However, we are unaware of studies evaluating the hazard of secondary symptom development over the disease course, which is an important consideration for patient prognostication. Further, the hazard of secondary symptom development stratified by initial clinical syndrome, FTD or ALS, has not yet been explored.

In this study, we examine whether the presence of a *C9orf72* expansion is associated with increased risk of secondary symptom development in individuals with ALS, excluding those with *SOD1* related disease lacking TDP-43 pathology, and behavioral variant FTD (bvFTD), excluding those with non-TDP-43 proteinopathy at autopsy. We focus our analyses on bvFTD since this is the most commonly observed FTD phenotype in concomitant FTD and ALS. We further ask whether the risk of secondary symptom development is modified by the initial clinical syndrome, bvFTD or ALS, beyond *C9orf72* expansion status. Using a targeted, retrospective evaluation of patients with a confirmed TDP-43 proteinopathy who were followed clinically from initial diagnosis until death, we are able to assess the presence or absence of secondary symptom development through the entire disease course. At autopsy, we evaluate the distribution of TDP-43 pathology in characteristic brain regions to evaluate the association between pathology and symptoms across the FTD-ALS spectrum.

Materials and methods

Participants

We retrospectively evaluated data from 241 deceased individuals from the University of Pennsylvania Integrated Neurodegenerative Disease Database.[31,32]

Inclusion was limited to individuals with:

1) An initial clinical diagnosis of ALS or bvFTD by a board-certified neurologist according to published clinical diagnostic criteria,[33,34] and
2) Complete records for date of birth, date of symptom onset for the initial clinical syndrome, and date of death, and
3) Blood DNA or postmortem frozen brain tissue screened for presence or absence of a *C9orf72* expansion (see *Genetic analysis*), and
4) Neuropathological confirmation of a TDP-43 proteinopathy at autopsy (see *Neuropathological evaluation*) *OR* the presence of a *C9orf72* expansion, and
5) Chart review

Two qualified reviewers performed a retrospective chart review of all available electronic and paper health records for each individual. Each reviewer independently assessed each case and recorded the presence or absence of secondary symptoms during disease course and, if present, the date of symptom onset of secondary symptoms. Secondary symptoms were defined as any clinical evidence of motor impairment in an individual with an initial clinical diagnosis of bvFTD or any clinical evidence of cognitive-behavioral impairment in an individual with an initial clinical diagnosis of ALS. When month was not determinable the default of January was used, and when day was not determinable the first of the month was used. Discrepancies between reviewers were reconciled by a third reviewer. Time to secondary symptom development was calculated as the difference in months between the date of symptom onset of the initial clinical syndrome and the date of symptom onset of secondary symptoms.

Genetic analysis

DNA was extracted from peripheral blood or frozen brain tissue following the manufacturer's protocols (QuickGene DNA whole blood kit (Autogen) for blood, and QIAamp DNA Mini Kit (Qiagen) for brain tissue). All individuals were tested for *C9orf72* hexanucleotide repeat expansions using a modified repeat-primed PCR as previously described. Cases were defined as having a pathogenic *C9orf72* expansion if >30 hexanucleotide repeats were identified. Individuals were further screened for pathogenic variants associated with FTD and/or ALS using exome/genome sequencing, and/or a custom targeted multi neurodegenerative disease

sequencing panel.[31] The sequencing data was analyzed using Geneticist Assistant software (Soft Genetics, State College, PA).

Neuropathological evaluation

Detailed neuropathological assessments were performed using established and uniform methods of fixation, tissue processing, IHC with well-characterized antibodies, and current neuropathological criteria, as has been described in detail elsewhere.[31,35,36] Briefly, 15 brain regions from one hemisphere, alternating right and left at random, are routinely sampled at autopsy, formalin-fixed, and processed for immunohistochemical staining using 1D3 (gift of Manuela Neumann and Elisabeth Kremmer) for phosphorylated TDP-43. Each brain region was semi-quantitatively scored for the burden of TDP-43 (0, absent; 0.5, rare; 1, mild; 2, moderate; 3, severe).

Statistical approach

We first assessed the effect of *C9orf72* expansion status (present or absent) and initial clinical syndrome (bvFTD or ALS) on the odds of developing secondary symptoms at any point from symptom onset of the initial clinical syndrome until death using binary logistic regression, controlling for age at initial clinical syndrome onset and sex. We next assessed the effect of *C9orf72* expansion status, alone and in combination with initial clinical syndrome on secondary symptom development using a time-to-event model.

The Kaplan-Meier method was used to estimate the cumulative incidence of secondary symptom development. An indidivudal was considered at risk for secondary symptom development from the time of symptom onset of the initial clinical syndrome until death. We subsequently considered an individual at risk until either death, tracheostomy, or permanent assisted ventilation, consistent with the definition of survival in some clinical trials.[37] Here, permanent assisted ventilation was defined as the date at which the individual reported using noninvasive positive pressure ventilation for more than 23 hours per day.

Cox proportional hazard analyses, controlling for age at initial clinical syndrome onset and sex, were used to examine the influence of *C9orf72* expansion status, alone and in combination with initial clinical syndrome, on secondary symptom development. The proportional hazards assumption was tested for each Cox regression model fit.[38]

Finally, the distribution of TDP-43 pathology was evaluated across the FTD-ALS spectrum, using FDR-adjusted Kruskal-Wallis tests to evaluate the difference in TDP-43 burden in each characteristic brain region across individuals grouped by initial clinical syndrome and secondary symptoms, followed by FDR-adjusted pairwise Dunn's tests to identify which groups were different. All statistical tests were two-sided. All analysis was done using R (version 4.2.3).

Data availability

Data requests can be completed through the Penn Neurodegenerative Data Sharing Committee webform: https://www.pennbindlab.com/data-sharing

Results

Secondary symptom development

69 individuals with initial bvFTD (32 [46%] *C9orf72* expansion present) and 172 individuals with initial ALS (68 [40%] *C9orf72* expansion present) were included in the study. Demographic, clinical, and genetic characteristics for all individuals are summarized in Table 1. Of the 69 individuals with initial bvFTD, 16 (23%) developed secondary motor symptoms. Of the 172 individuals with initial ALS, 23 (13%) developed secondary cognitive-behavioral symptoms.

Logistic regression

Binary logistic regression revealed increased odds of developing secondary symptoms in those with *C9orf72* expansions relative to those without (OR=4.25 [95% CI 1.97-9.14], $p<0.001$). Initial clinical syndrome (bvFTD or ALS) was not associated with the odds of developing secondary symptoms (OR=0.55 [95% CI 0.26-1.17], p=0.12). Neither age at initial clinical syndrome onset (OR=0.97 [95% CI 0.94-1.01], p=0.18) nor sex (OR=0.62 [95% CI 0.30-1.28], p=0.20) contributed to the odds of developing secondary symptoms.

Cox proportional hazards

Those with *C9orf72* expansions had an increased risk for developing secondary symptoms compared to those without (HR= 4.77 [95% CI 2.33- 9.79], p<0.001). Kaplan-Meier cumulative incidence plots, stratified by *C9orf72* expansion status alone or in combination with with initial clinical syndrome are displayed in Figure 1. In persons with *C9orf72* expansions, the probability of a given person developing secondary symptoms reached 0.5 (50%) at 120 months (10 years) after symptom onset of the initial clinical syndrome (Figure 1). In persons without *C9orf72* expansions, the time at which the probability of a given person developing secondary symptoms would reach 0.5 is unable to be estimated due to the infrequent development of secondary symptoms in this group. In combination with *C9orf72* carrier status, initial clinical syndrome was not associated with the hazard for developing secondary symptoms (HR=1.18 [95% CI 0.59-2.36], p= 0.65). Neither age at initial clinical syndrome onset (HR= .99 [95% CI range across models .95-1.02]) nor sex (HR=.68 [95% CI range across models 0.36-1.28]) were associated with the hazard for developing secondary symptoms in either model. Tracheostomy was administered to 6 of 241 participants (2.49%) and 6 of 241 participants (2.49%) used permanent assisted ventilation. When we defined survival by death, tracheostomy, or permanent assisted ventilation, we observed similar results to those using death only; individuals with *C9orf72* expansions had an increased risk for developing secondary symptoms compared to those without (HR= 4.70 [95% CI 2.30-9.64], p<0.001).

Regional TDP-43 burden

At autopsy, the distribution of TDP-43 pathology across characteristic brain regions reflected both the initial clinical syndrome and secondary symptoms. First, this was done in characteristic bvFTD regions, specifically the cingulate gyrus, middle frontal cortex, angular gyrus, and superior/middle temporal cortex (Figure 2). Pairwise Dunn's tests revealed a lower burden of TDP- 43 pathology in ALS cases without secondary cognitive-behavioral symptoms compared to bvFTD cases (with or without secondary motor symptoms) across all characteristic bvFTD regions (all p<.001). Further, a lower burden of TDP-43 pathology was observed in ALS cases without secondary cognitive-behavioral symptoms compared to ALS

cases with secondary cognitive-behavioral symptoms in middle frontal cortex, angular gyrus, and superior/middle temporal cortex (all p<.01). Second, we examined TDP-43 burden in characteristic ALS regions, motor cortex and spinal cord. In the spinal cord, a lower burden of TDP-43 pathology was observed in bvFTD cases without secondary motor symptoms compared to ALS cases (with or without secondary cognitive-behavioral symptoms) and bvFTD cases with secondary motor symptoms (all p<.0001). However, no significant differences in TDP-43 burden were observed in the motor cortex across individuals grouped by initial clinical syndrome and secondary symptoms using Kruskal-Wallis test (p=.28).

Discussion

All individuals with an initial clinical diagnosis of bvFTD or ALS with an underlying TDP-43 proteinopathy are at risk for developing secondary cognitive-behavioral or motor symptoms, respectively, but this risk is heightened for those with disease due to a *C9orf72* hexanucleotide repeat expansion. Regardless of genetic status, there is a modest risk for the development of secondary symptoms in the first year after symptom onset of the initial clinical syndrome, with 7.0% of persons with *C9orf72* expansions and 4.3% of those without without *C9orf72* expansions developing secondary symptoms in this timeframe. However, by death, 28.0% of those with *C9orf72* expansions develop secondary symptoms compared to only 7.8% of those without *C9orf72* expansions, in line with previous estimates.[26–28] While some studies report a median interval of less than one year between the onset of the initial clinical syndrome and secondary symptoms in those with a *C9orf72* expansion, we observed a median of 2 years.[39] In our sample, the cumulative incidence curves begin to deviate at 31.6 months after symptom onset of the initial clinical syndrome, when the probability of a given person developing secondary symptoms is 0.21 (95% CI 0.12-0.29) for those with *C9orf72* expansions, and 0.07 (95% CI 0.02-0.11) for those without *C9orf72* expansions (Figure 1). By 120 months (10 years) after symptom onset of the initial clinical syndrome, a person with a *C9orf72* expansion has a 50% probability of developing secondary symptoms. However, the mean time between symptom onset of the initial clinical syndrome and death is shorter than 120 months across ALS and bvFTD groups, so few individuals remain at risk for

secondary symptom development at this time point. We observed two persons with *C9orf72* expansions who develop secondary symptoms 10+ years after symptom onset of the initial clinical syndrome, similar to some previously reported intervals.[40]

In this study, we found that the cumulative incidence of secondary symptom development did not differ by initial clinical syndrome, bvFTD or ALS. The presence of secondary symptom development was associated with a shorter interval between symptom onset of the initial clinical syndrome and death for both initial bvFTD and ALS, aligning with previous research,[7–10] although these differences were not significant in our sample. The time between symptom onset of the initial clinical syndrome and death was shortest for individuals with initial ALS, with or without secondary symptom development, aligning with prior work that found that long-term survivors in the FTD-ALS spectrum were more likely to be individuals with cognitive symptoms at onset.[41] We also observed a younger age at onset of cognitive-behavioral symptoms for individuals with initial bvFTD who develop secondary motor symptoms (52.84 [6.35]) than those who never develop secondary symptoms (60.89 [9.36], Table 1).

At autopsy, the distribution of TDP-43 pathology in characteristic regions reflected both the initial syndrome and secondary symptoms, with relatively preserved spinal cord only in bvFTD cases without secondary motor symptoms and relatively preserved neocortical regions only in ALS cases without secondary cognitive-behavioral symptoms. These data align with previous work highlighting the distribution and severity of TDP-43 pathology relates to the clinical expression of dementia and motor impairments across the spectrum of TDP-43 proteinopathies[42–44] and provides important cross-validation for our clinical designations of ALS, bvFTD, and secondary symptoms.

Future studies are necessary to determine a biological explanation for why individuals with a *C9orf72* expansion have a higher risk for developing secondary symptoms relative to those without despite sharing common underlying TDP-43 pathology. More people without *C9orf72* expansions than those with them may ultimately develop secondary symptoms, despite secondary symptom development being a lower probability event, as most individuals with ALS and FTD do not have a *C9orf72* expansion, and studies are needed to elucidate risk factors in this population.[45–47]

As with all epidemiological studies there are several caveats to consider in our approach. In order to ensure TDP-43 pathology in this study, we relied on neuropathological confirmation,

which necessitated a retrospective evaluation of cases. One should consider any potential sources of bias introduced by our primary focus on individuals who participated in brain donation, who tend to be more educated and non-representative of the population per se. Further, we focused on bvFTD, but future work should evaluate secondary language and other cognitive domain impairment in ALS beyond motor impairment. Prospective collection of both reported symptom onset as well as detailed electrophysiological support and neuropsychological testing would strengthen the study; however our postmortem data support our clinical groupings (Figure 2). It is also necessary for future studies to address other potential modifiers of risk for concomitant cognitive-behavioral and motor impairment such as cognitive and motor reserve factors[48] and other environmental[49] and genetic[50,51] modifiers.

These findings should encourage clinicians to have elevated vigilance for the onset of secondary cognitive-behavioral and motor symptoms in patients with a *C9orf72* expansion regardless of initial clinical syndrome and may warrant dual referrals between cognitive and neuromuscular clinics. Early work likely failed to observe an association between secondary symptoms and survival in ALS due to a focus on memory rather than FTD-like cognitive/behavioral impairment.[12] Therefore, it is critical to properly evaluate these patients. This information may also be helpful for patients and families in terms of prognosis and understanding the implications of a *C9orf72* expansion in their family.

Table 1 Sample Characteristics. Demographic, clinical, and genetic data for all individuals, split by initial clinical syndrome (bvFTD or ALS) and the presence of secondary motor (bvFTD+Motor) or cognitive-behavioral (ALS+Cog) symptoms. For continuous variables, mean and standard deviation are provided; p values represent Kruskal-Wallis tests for group comparisons, and differences from †ALS, ‡ALS+Cog, §bvFTD, or ¶bvFTD+Motor based on FDR-adjusted significant pairwise Dunn's tests are indicated. For categorical variables, count and percentage are provided; p values represent χ^2 tests for group comparisons, and differences from †ALS, ‡ALS+Cog, §bvFTD, or ¶bvFTD+Motor based on FDR-adjusted significant pairwise χ^2 tests are indicated.

	ALS	**ALS+Cog**	**bvFTD**	**bvFTD+Motor**	**p value**
n	149	23	53	16	
Sex (Male, %)	91 (61.1)	10 (43.5)	30 (56.6)	9 (56.2)	0.45
Race (%)					0.46
African American	1 (0.7)	0 (0.0)	0 (0.0)	0 (0.0)	
Black	3 (2.0)	2 (8.7)	1 (1.9)	0 (0.0)	
Multi-racial	0 (0.0)	0 (0.0)	1 (1.9)	0 (0.0)	
White	142 (95.3)	21 (91.3)	51 (96.2)	15 (93.8)	
Unknown	3 (2.0)	0 (0.0)	0 (0.0)	1 (6.2)	
Ethnicity (%)					0.77
Latino	3 (2.0)	0 (0.0)	1 (1.9)	0 (0.0)	
Non-Latino	142 (95.3)	23 (100.0)	52 (98.1)	16 (100.0)	
Unknown	4 (2.7)	0 (0.0)	0 (0.0)	0 (0.0)	
Age at death (years, mean (SD))	63.93 (10.57)	63.18 (9.39)	68.88 (10.95) †¶	59.10 (8.28)	0.005
Age at initial clinical syndrome symptom onset (years, mean (SD))	59.74 (10.91)	59.31 (9.47)	60.89 (9.36)	52.84 (6.35)†§	0.02
Initial clinical syndrome diagnostic delay (months, mean (SD))	16.84 (19.00) §¶	21.78 (28.58) §¶	46.83 (36.27)	56.87 (51.19)	<0.001
Initial clinical syndrome symptom onset to secondary symptom onset (months, mean (SD))	-	26.59 (23.14)	-	50.59 (52.81)	0.48
Initial clinical syndrome symptom onset to death (months, mean (SD))	50.38 (50.75)	46.38 (33.82)	95.87 (53.65) †‡	75.07 (59.95)	<0.001

***C9orf72* expansion present(%)**	50 (33.6)	18 (78.3)[†§]	22 (41.5)	10 (62.5)	<0.001
***C9orf72* expansion absent**					0.10
No known genetic etiology	99 (100.0)	5 (100.0)	28 (90.3)	6 (100.0)	
GBE1	0 (0.0)	0 (0.0)	1 (3.2)	0 (0.0)	
TBK1	0 (0.0)	0 (0.0)	2 (6.5)	0 (0.0)	

Figure 1 C9orf72 hexanucleotide repeat expansions increase risk for secondary symptom development. Kaplan-Meier cumulative incidence plots are displayed stratified by (**A**) the presence (red) or absence (blue) of a *C9orf72* expansion alone and (**B**) combined with initial clinical syndrome, ALS (solid line) or bvFTD (dashed line). Vertical rises indicate the development of secondary cognitive-behavioral or motor symptoms. Tick marks indicate censoring due to death. Shading represents 95% confidence intervals. The table shows the number of living individuals in the sample who have not yet developed secondary symptoms at a given time point.

A



Number at risk

C9orf72 expansion absent	141	114	69	46	34	21	16	10	6	6	4	4	3	1
C9orf72 expansion present	100	69	33	20	8	6	2	1	0	0	0	0	0	0

B



Number at risk

C9−initial bvFTD	37	33	27	20	18	12	9	5	2	2	1	1	0	0
C9+ initial bvFTD	32	27	24	17	8	6	2	1	0	0	0	0	0	0
C9−initial ALS	104	81	42	26	16	9	7	5	4	4	3	3	3	1
C9+ initial ALS	68	42	9	3	0	0	0	0	0	0	0	0	0	0

Figure 2 Regional TDP-43 burden reflects initial clinical syndrome and secondary symptoms. The burden of TDP-43 pathology was examined across individuals grouped by initial clinical syndrome and secondary symptoms. This was done in characteristic bvFTD regions (top row: cingulate gyrus, angular gyrus, middle frontal cortex, and superior/middle temporal cortex), and characteristic ALS regions (bottom row: motor cortex and spinal cord). The FDR adjusted p-values for each Kruskal-Wallis test are displayed by region. Asterisks represent FDR-adjusted significant pairwise Dunn's tests within region (****p<.0001, ***p<.001, **p<.01, *p<.05). Jitter was added around the semi-quantitatively scored TDP-43 burden (0, absent; 0.5, rare; 1, mild; 2, moderate; 3, severe) for individual data point visualization.



Acknowledgements

The authors would like to thank Laura Hennessy, Katerina Placek, Carrie Caswell, and Kaylee Naczi who contributed to the recruitment, data collection, and characterization of individuals included in this study.

Funding

National Institutes of Health grant F32AG079618 (BES), P01AG066597 (CTM), NS109260 (DJI), P30AG072979 (EBL), Penn Institute on Aging, and The DeCrane Family Fund for Primary Progressive Aphasia

Competing interests

EBL reports consulting fees from WaveBreak Therapeutics. LD reports consulting fees from Passage Bio, Biogen, and Sano Genetics. The authors report no other relevant competing interests.

References

1. Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 2017;18(3-4):153-174. doi:10.1080/21678421.2016.1267768

2. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. *Science*. 2006;314(5796):130-133. doi:10.1126/science.1134108

3. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in non-coding region of C9ORF72 causes chromosome 9p-linked frontotemporal dementia and amyotrophic lateral sclerosis. *Neuron*. 2011;72(2):245-256. doi:10.1016/j.neuron.2011.09.011

4. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron*. 2011;72(2):257-268. doi:10.1016/j.neuron.2011.09.010

5. Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. *Lancet Neurol*. 2012;11(4):323-330. doi:10.1016/S1474-4422(12)70043-1

6. Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry*. 2017;88(7):540-549. doi:10.1136/jnnp-2016-315018

7. Olney RK, Murphy J, Forshew D, et al. The effects of executive and behavioral dysfunction on the course of ALS. *Neurology*. 2005;65(11):1774-1777. doi:10.1212/01.wnl.0000188759.87240.8b

8. Josephs KA, Knopman DS, Whitwell JL, et al. Survival in two variants of tau-negative frontotemporal lobar degeneration: FTLD-U vs FTLD-MND. *Neurology*. 2005;65(4):645-647. doi:10.1212/01.wnl.0000173178.67986.7f

9. Hu WT, Shelnutt M, Wilson A, et al. Behavior matters--cognitive predictors of survival in amyotrophic lateral sclerosis. *PLoS One*. 2013;8(2):e57584. doi:10.1371/journal.pone.0057584

10. Hodges JR, Davies R, Xuereb J, Kril J, Halliday G. Survival in frontotemporal dementia. *Neurology*. 2003;61(3):349-354. doi:10.1212/01.wnl.0000078928.20107.52

11. Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. *Neurology*. 2005;65(4):586-590. doi:10.1212/01.wnl.0000172911.39167.b6

12. Rippon GA, Scarmeas N, Gordon PH, et al. An Observational Study of Cognitive Impairment in Amyotrophic Lateral Sclerosis. *Archives of Neurology*. 2006;63(3):345-352. doi:10.1001/archneur.63.3.345

13. Montuschi A, Iazzolino B, Calvo A, et al. Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. *J Neurol Neurosurg Psychiatry*. 2015;86(2):168-173. doi:10.1136/jnnp-2013-307223

14. Phukan J, Elamin M, Bede P, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. *J Neurol Neurosurg Psychiatry*. 2012;83(1):102-108. doi:10.1136/jnnp-2011-300188

15. McHutchison CA, Wuu J, McMillan CT, et al. Temporal course of cognitive and behavioural changes in motor neuron diseases. *J Neurol Neurosurg Psychiatry*. 2024;95(4):316-324. doi:10.1136/jnnp-2023-331697

16. McMillan CT, Wuu J, Rascovsky K, et al. Defining Cognitive Impairment in Amyotrophic Lateral Sclerosis: An Evaluation of Empirical Approaches. *Amyotroph Lateral Scler Frontotemporal Degener*. 2022;23(7-8):517-526. doi:10.1080/21678421.2022.2039713

17. Johnson JK, Diehl J, Mendez MF, et al. Frontotemporal lobar degeneration: demographic characteristics of 353 patients. *Arch Neurol*. 2005;62(6):925-930. doi:10.1001/archneur.62.6.925

18. Rosso SM, Donker Kaat L, Baks T, et al. Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. *Brain*. 2003;126(Pt 9):2016-2022. doi:10.1093/brain/awg204

19. Burrell JR, Kiernan MC, Vucic S, Hodges JR. Motor neuron dysfunction in frontotemporal dementia. *Brain*. 2011;134(Pt 9):2582-2594. doi:10.1093/brain/awr195

20. Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. *Neurology*. 2002;59(7):1077-1079. doi:10.1212/WNL.59.7.1077

21. Gijselinck I, Van Langenhove T, van der Zee J, et al. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. *Lancet Neurol*. 2012;11(1):54-65. doi:10.1016/S1474-4422(11)70261-7

22. Moore KM, Nicholas J, Grossman M, et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. *Lancet Neurol*. 2020;19(2):145-156. doi:10.1016/S1474-4422(19)30394-1

23. Simón-Sánchez J, Dopper EGP, Cohn-Hokke PE, et al. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. *Brain*. 2012;135(3):723-735. doi:10.1093/brain/awr353

24. Samra K, MacDougall AM, Peakman G, et al. Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales. *J Neurol*. 2023;270(3):1466-1477. doi:10.1007/s00415-022-11442-y

25. Mahoney CJ, Beck J, Rohrer JD, et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. *Brain*. 2012;135(Pt 3):736-750. doi:10.1093/brain/awr361

26. Byrne S, Elamin M, Bede P, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. *Lancet Neurol*. 2012;11(3):232-240. doi:10.1016/S1474-4422(12)70014-5

27. Van Langenhove T, Piguet O, Burrell JR, et al. Predicting Development of Amyotrophic Lateral Sclerosis in Frontotemporal Dementia. *Journal of Alzheimer's Disease*. 2017;58(1):163-170. doi:10.3233/JAD-161272

28. Smith BN, Newhouse S, Shatunov A, et al. The C9ORF72 expansion mutation is a common cause of ALS+/−FTD in Europe and has a single founder. *Eur J Hum Genet*. 2013;21(1):102-108. doi:10.1038/ejhg.2012.98

29. Nagao S, Yokota O, Nanba R, et al. Progressive supranuclear palsy presenting as primary lateral sclerosis but lacking parkinsonism, gaze palsy, aphasia, or dementia. *J Neurol Sci*. 2012;323(1-2):147-153. doi:10.1016/j.jns.2012.09.005

30. Josephs KA, Katsuse O, Beccano-Kelly DA, et al. Atypical Progressive Supranuclear Palsy With Corticospinal Tract Degeneration. *Journal of Neuropathology & Experimental Neurology*. 2006;65(4):396-405. doi:10.1097/01.jnen.0000218446.38158.61

31. Toledo JB, Van Deerlin VM, Lee EB, et al. A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. *Alzheimers Dement*. 2014;10(4):477-484.e1. doi:10.1016/j.jalz.2013.06.003

32. Xie SX, Baek Y, Grossman M, et al. Building An Integrated Neurodegenerative Disease Database At An Academic Health Center. *Alzheimers Dement*. 2011;7(4):e84-e93. doi:10.1016/j.jalz.2010.08.233

33. Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord*. 2000;1(5):293-299. doi:10.1080/146608200300079536

34. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain*. 2011;134(Pt 9):2456-2477. doi:10.1093/brain/awr179

35. Mackenzie IRA, Neumann M, Baborie A, et al. A harmonized classification system for FTLD-TDP pathology. *Acta Neuropathol*. 2011;122(1):111-113. doi:10.1007/s00401-011-0845-8

36. Mackenzie IRA, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. *Acta Neuropathol*. 2010;119(1):1-4. doi:10.1007/s00401-009-0612-2

37. Gordon PH, Corcia P, Lacomblez L, et al. Defining Survival as an Outcome Measure in Amyotrophic Lateral Sclerosis. *Archives of Neurology*. 2009;66(6):758-761. doi:10.1001/archneurol.2009.1

38. Grambsch PM, Therneau TM. Proportional Hazards Tests and Diagnostics Based on Weighted Residuals. *Biometrika*. 1994;81(3):515-526. doi:10.2307/2337123

39. Snowden JS, Harris J, Richardson A, et al. Frontotemporal dementia with amyotrophic lateral sclerosis: A clinical comparison of patients with and without repeat expansions in C9orf72. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 2013;14(3):172-176. doi:10.3109/21678421.2013.765485

40. Toyoshima Y, Tan CF, Kozakai T, Tanaka M, Takahashi H. Is motor neuron disease-inclusion dementia a forme fruste of amyotrophic lateral sclerosis with dementia? An autopsy case further supporting the disease concept. *Neuropathology*. 2005;25(3):214-219. doi:10.1111/j.1440-1789.2005.00599.x

41. Hu WT, Seelaar H, Josephs KA, et al. Survival Profiles of Patients With Frontotemporal Dementia and Motor Neuron Disease. *Archives of Neurology*. 2009;66(11):1359-1364. doi:10.1001/archneurol.2009.253

42. Brettschneider J, Del Tredici K, Irwin DJ, et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). *Acta Neuropathol*. 2014;127(3):423-439. doi:10.1007/s00401-013-1238-y

43. Brettschneider J, Arai K, Del Tredici K, et al. TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. *Acta Neuropathol*. 2014;128(3):423-437. doi:10.1007/s00401-014-1299-6

44. Geser F, Prvulovic D, O'Dwyer L, et al. On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. *Progress in Neurobiology*. 2011;95(4):649-662. doi:10.1016/j.pneurobio.2011.08.011

45. Goldman JS, Farmer JM, Van Deerlin VM, Wilhelmsen KC, Miller BL, Grossman M. Frontotemporal dementia: genetics and genetic counseling dilemmas. *Neurologist*. 2004;10(5):227-234. doi:10.1097/01.nrl.0000138735.48533.26

46. Rohrer JD, Guerreiro R, Vandrovcova J, et al. The heritability and genetics of frontotemporal lobar degeneration. *Neurology*. 2009;73(18):1451-1456. doi:10.1212/WNL.0b013e3181bf997a

47. Byrne S, Walsh C, Lynch C, et al. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry*. 2011;82(6):623-627. doi:10.1136/jnnp.2010.224501

48. Rhodes E, Alfa S, Jin HA, et al. Cognitive reserve in ALS: the role of occupational skills and requirements. *Amyotroph Lateral Scler Frontotemporal Degener*. Published online April 9, 2024:1-10. doi:10.1080/21678421.2024.2336113

49. Massimo L, Zee J, Xie SX, et al. Occupational attainment influences survival in autopsy-confirmed frontotemporal degeneration. *Neurology*. 2015;84(20):2070-2075. doi:10.1212/WNL.0000000000001595

50. Placek K, Baer GM, Elman L, et al. UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. *Neurobiol Aging*. 2019;73:190-199. doi:10.1016/j.neurobiolaging.2018.09.031

51. Placek K, Benatar M, Wuu J, et al. Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. *EMBO Mol Med*. 2021;13(1):e12595. doi:10.15252/emmm.202012595